Biotech | December 13, 2021
Zydus to begin Phase II (a) clinical trial of ZYIL1 in Australia
It is a novel oral NLRP3 inflammasome inhibitor
It is a novel oral NLRP3 inflammasome inhibitor
Under this scheme, the company will make a committed investment in plant and machinery, get incentives on incremental sales of pharmaceutical products
Results from the ongoing vodobatinib clinical study are being presented for the second consecutive year at the ASH annual meeting, underlining the promising potential of the drug for the treatment of heavily pre-treated CML
The company is focused on the development of novel treatments for RNA viruses
Approvals accorded under Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ drug intermediates and Active Pharmaceutical Ingredients (APIs
The setting up of these 8 plants will lead to a total committed investment of Rs. 260.40 crore
_256_384.jpg)
Primary endpoints and secondary endpoints for which data are available were met in trial dominated by Covid-19 variants
The tablets are available in 150 mg and 225 mg strengths in bottle count sizes of 30 and 90.
The platform’s technology works as a compression algorithm for molecular testing
The tablets are indicated for the treatment of pulmonary arterial hypertension
Subscribe To Our Newsletter & Stay Updated
